Literature DB >> 17919877

PTEN and VEGF: possible predictors for sentinel lymph node micro-metastasis in breast cancer.

Li Zhu1, Wings T Y Loo, W C Chow Louis.   

Abstract

INTRODUCTION: The loss of PTEN expression and VEGF overexpression has been found to be correlated with metastasis in breast cancer patients. Despite significant advances in micro-metastasis detection methods, little is known about the relationship between micro-metastasis and primary tumors. The purpose of this study was to assess the association of VEGF and PTEN expression with micro-metastasis in breast cancer.
MATERIALS AND METHODS: As destination sites for micro-metastasis, we examined peripheral blood (BD), bone marrow (BM) and sentinel lymph node (SLN) from 53 breast cancer patients. Protein and gene expressions of VEGF and PTEN at the primary site were determined by immunohistochemistry (IHC). BD and BM samples were processed using immunocytochemistry (ICC). SLNs were examined by hematoxylin and eosin (H&E) staining and IHC.
RESULTS: Percentages of the patients with micro-metastasis were 24.5% for BD, 56.6% for BM, 26.4% in SLN by H&E and 41.5% in SLN by IHC. VEGF overexpression was strongly correlated to loss of PTEN expression (P=0.001, r=-0.446). VEGF overexpression and loss of PTEN expression were significantly associated with SLN micro-metastasis by either H&E or IHC (P<0.001). On the contrary, there is no significant correlation between their expression and micro-metastasis in BD and BM.
CONCLUSIONS: Our results indicate possible value of using these biological markers to predict the risk of micro-metastasis in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17919877     DOI: 10.1016/j.biopha.2007.08.015

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  miR-29b regulates migration of human breast cancer cells.

Authors:  Chen Wang; Zhen Bian; Da Wei; Jian-guo Zhang
Journal:  Mol Cell Biochem       Date:  2011-02-26       Impact factor: 3.396

2.  Association of sporadic breast cancer with PTEN/MMAC1/TEP1 promoter hypermethylation.

Authors:  Vallian Sadeq; Nassiri Isar; Tavassoli Manoochehr
Journal:  Med Oncol       Date:  2010-03-17       Impact factor: 3.064

3.  PTEN mutation spectrum in breast cancers and breast hyperplasia.

Authors:  Julun Yang; Yan Ren; Li Wang; Baolin Li; Yue Chen; Wenxing Zhao; Wenmang Xu; Tao Li; Fang Dai
Journal:  J Cancer Res Clin Oncol       Date:  2010-03-19       Impact factor: 4.553

4.  Correlation Between Onco-suppressors PTEN and NM23 and Clinical Outcome in Patients With T1 Breast Cancer.

Authors:  Luciano Izzo; Daniela Messineo; Pierfrancesco DI Cello; Virgilio Nicolanti; Antonio Sterpetti; Sara Izzo; Paolo Izzo
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

5.  Pathway profiling and rational trial design for studies in advanced stage cervical carcinoma: a review and a perspective.

Authors:  Susy M E Scholl; Gemma Kenter; Christian Kurzeder; Philippe Beuzeboc
Journal:  ISRN Oncol       Date:  2011-07-06

6.  Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma.

Authors:  Liqiang Qi; Joost Bart; Lu Ping Tan; Inge Platteel; Tineke van der Sluis; Sippie Huitema; Geert Harms; Li Fu; Harry Hollema; Anke van den Berg
Journal:  BMC Cancer       Date:  2009-05-28       Impact factor: 4.430

7.  Concomitant depletion of PTEN and p27 and overexpression of cyclin D1 may predict a worse prognosis for patients with post-operative stage II and III colorectal cancer.

Authors:  Jing Li; Lin-Lin Yin; Ke-Li Su; Gang-Feng Zhang; Jing Wang
Journal:  Oncol Lett       Date:  2014-07-14       Impact factor: 2.967

8.  Anti-metastasis effect of fucoidan from Undaria pinnatifida sporophylls in mouse hepatocarcinoma Hca-F cells.

Authors:  Peisheng Wang; Zhichao Liu; Xianli Liu; Hongming Teng; Cuili Zhang; Lin Hou; Xiangyang Zou
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.